Special agents hunting down women silent killer: The emerging role of the p38 kinase

Valentina Grossi, Cristiano Simone

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Ovarian cancer is sensitive to chemotherapy with platinum compounds; however, the therapy success rate is significantly lowered by a high incidence of recurrence and by the acquisition of drug resistance. These negative outcomes mainly depend on altered apoptotic and drug resistance pathways, determining the need for the design of new therapeutic strategies to improve patient survival. This challenge has become even more critical because it has been recognized that hindering uncontrolled cell growth is not sufficient as the only curative approach. In fact, while current therapies are mostly conceived to impair survival of highly proliferating cells, several lines of research are now focusing on cancer-specific features to specifically target malignant cells with the aim of avoiding drug resistance and reducing adverse effects. Recently, great interest has been generated by the identification of metabolic reprogramming mechanisms occurring in cancer cells, such as the increase in glycolysis levels. In this light, pharmacologic manipulation of relevant pathways involved in cancer-specific metabolism and drug resistance could prove an effective approach to treat ovarian cancer patients.

Original languageEnglish
Article number382159
JournalJournal of Oncology
DOIs
Publication statusPublished - 2012

Fingerprint

Drug Resistance
Phosphotransferases
Ovarian Neoplasms
Platinum Compounds
Neoplasms
Survival
Glycolysis
Therapeutics
Recurrence
Drug Therapy
Cell Line
Incidence
Growth
Research

ASJC Scopus subject areas

  • Oncology

Cite this

Special agents hunting down women silent killer : The emerging role of the p38 kinase. / Grossi, Valentina; Simone, Cristiano.

In: Journal of Oncology, 2012.

Research output: Contribution to journalArticle

@article{38e8d7764267494ca6961829e6b3bdb8,
title = "Special agents hunting down women silent killer: The emerging role of the p38 kinase",
abstract = "Ovarian cancer is sensitive to chemotherapy with platinum compounds; however, the therapy success rate is significantly lowered by a high incidence of recurrence and by the acquisition of drug resistance. These negative outcomes mainly depend on altered apoptotic and drug resistance pathways, determining the need for the design of new therapeutic strategies to improve patient survival. This challenge has become even more critical because it has been recognized that hindering uncontrolled cell growth is not sufficient as the only curative approach. In fact, while current therapies are mostly conceived to impair survival of highly proliferating cells, several lines of research are now focusing on cancer-specific features to specifically target malignant cells with the aim of avoiding drug resistance and reducing adverse effects. Recently, great interest has been generated by the identification of metabolic reprogramming mechanisms occurring in cancer cells, such as the increase in glycolysis levels. In this light, pharmacologic manipulation of relevant pathways involved in cancer-specific metabolism and drug resistance could prove an effective approach to treat ovarian cancer patients.",
author = "Valentina Grossi and Cristiano Simone",
year = "2012",
doi = "10.1155/2012/382159",
language = "English",
journal = "Journal of Oncology",
issn = "1687-8450",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Special agents hunting down women silent killer

T2 - The emerging role of the p38 kinase

AU - Grossi, Valentina

AU - Simone, Cristiano

PY - 2012

Y1 - 2012

N2 - Ovarian cancer is sensitive to chemotherapy with platinum compounds; however, the therapy success rate is significantly lowered by a high incidence of recurrence and by the acquisition of drug resistance. These negative outcomes mainly depend on altered apoptotic and drug resistance pathways, determining the need for the design of new therapeutic strategies to improve patient survival. This challenge has become even more critical because it has been recognized that hindering uncontrolled cell growth is not sufficient as the only curative approach. In fact, while current therapies are mostly conceived to impair survival of highly proliferating cells, several lines of research are now focusing on cancer-specific features to specifically target malignant cells with the aim of avoiding drug resistance and reducing adverse effects. Recently, great interest has been generated by the identification of metabolic reprogramming mechanisms occurring in cancer cells, such as the increase in glycolysis levels. In this light, pharmacologic manipulation of relevant pathways involved in cancer-specific metabolism and drug resistance could prove an effective approach to treat ovarian cancer patients.

AB - Ovarian cancer is sensitive to chemotherapy with platinum compounds; however, the therapy success rate is significantly lowered by a high incidence of recurrence and by the acquisition of drug resistance. These negative outcomes mainly depend on altered apoptotic and drug resistance pathways, determining the need for the design of new therapeutic strategies to improve patient survival. This challenge has become even more critical because it has been recognized that hindering uncontrolled cell growth is not sufficient as the only curative approach. In fact, while current therapies are mostly conceived to impair survival of highly proliferating cells, several lines of research are now focusing on cancer-specific features to specifically target malignant cells with the aim of avoiding drug resistance and reducing adverse effects. Recently, great interest has been generated by the identification of metabolic reprogramming mechanisms occurring in cancer cells, such as the increase in glycolysis levels. In this light, pharmacologic manipulation of relevant pathways involved in cancer-specific metabolism and drug resistance could prove an effective approach to treat ovarian cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=84859798330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859798330&partnerID=8YFLogxK

U2 - 10.1155/2012/382159

DO - 10.1155/2012/382159

M3 - Article

C2 - 22481926

AN - SCOPUS:84859798330

JO - Journal of Oncology

JF - Journal of Oncology

SN - 1687-8450

M1 - 382159

ER -